Background: Transurethral resection of the bladder (TURB) tumor was first described by Stern and McCarthy in 1931, and is still considered the gold standard in diagnosis and treatment of non-muscle-invasive bladder cancer. The quality of TURB affects accuracy of histopathologic evaluation, and subsequently impacts the risk of recurrence and patient outcome. New methods that aim to improve the effectiveness of TURB are reviewed, and recent studies are discussed, including resection methods and image enhancement techniques. Material and methods: Between January 2016 and April 2019, within the Urology Clinic of Nicolae Testemitanu State University of Medicine and Pharmacy 108 patients were surgically treated with bladder tumor pathology. Patients were divided in two groups: En-bloc resection group which includes 51 patients and transurethral resection group with 57 patients, the obtained data were comparatively analyzed. Results: Tumor analysis showed that the majority of the patients’ tumors were localized on lateral urinary bladder walls, single bladder tumors were detected in 64 (59%) cases, tumor sizes up to 3 cm were detected in 74 (69%) patients included in the study. Detrusor muscles were detected in 49 (96%) cases of En-bloc group and 45 (79%) cases of TURB group. Most recurrences occurred in patients with high-grade histological result, recurrence rate in En-bloc group occurred in 18% and in TURB group in 37%. Conclusions: The En-bloc resection technique of non-muscle-invasive bladder tumor proved to be a safe and effective method compared to the conventional transurethral resection technique (TURB). This method provides more favorable results for obtaining better quality tumor samples (present of detrusor muscle) that allow to establish correct diagnosis and staging of the disease and reduces the number of recurrences.

This study presents the importance of entomotherapy in chronic non bacterial prostatitis. Administration of combine therapy with adenoprosine at the patients with various forms of non bacterial CP (inflammatory and non-inflammatory), demonstrate antioxidant and anti-inflammatory action, in combination with modern complementary methods, signifi cantly increases the effectiveness of treatment, improves patients’ quality of life and optimizes duration of treatment – treatment can be reduced from 3 months to 30 days. According to the results of the study, of all patients investigated with chronic non bacterial prostatitis, with or without symptoms of urinary disorders, only 27 (82%) of patients did not detect another condition, responsible for the above-mentioned disorders.

Laser prostate surgery is currently considered as being an alternative to other surgical approaches like mono or bipolar transurethral resection and classical open surgery. The implementation of transurethral Thulium: YAG laser vapoenucleation of the prostate opens up new avenues in the treatment of benign prostatic hyperplasia. Therefore, the use of Th uVEP and the subsequent fragmentation of vapoenucleated adenomatous nodules may completely change the surgical approach in the treatment of benign prostatic hyperplasia. The study included 23 patients with benign prostatic hyperplasia, who underwent minim invasive surgical treatment via transurethral Thulium: YAG laser vapoenucleation within the Urology Clinic of „Nicolae Testemitanu” SUMPh. The patients tolerated the surgical procedure well. Patients, with mean age of 62.4±3 years, were assessed at 3, 6, and 12 months aft er the surgery. A constant improvement of the IPSS and QoL scores was determined. A 15-point IPSS and 2-point Qol decrease was registered. No signifi cant decrease in IIFE-5 score was reported. The highest Qmax and Qmean increase was registered at 12 months: 150% and 139.4% respectively. The mean urine output increased to 59ml or 47.9%. The mean prostate volume decreased to 41±5cm3 (-4.1%), whereas the volume of residual urine showed a decrease of about 66±18ml (-77%). Given the excellent effi cacy of minimally invasive ThuVEP, it might be recommended as a surgical method of choice in the treatment of benign prostatic hyperplasia.